NOTICES
STATE HORSE RACING COMMISSION
Amended Schedule of Therapeutic Medications
[46 Pa.B. 6204]
[Saturday, October 1, 2016]The State Horse Racing Commission (Commission), in accordance with the authority in section 2812-D(6) of The Administrative Code of 1929 (71 P.S. § 720.32(6)) and more specifically 58 Pa. Code § 163.304 (relating to substances of therapeutic value), adopts the Amended Schedule of Therapeutic Medications (Schedule) established by the Nationally-recognized Racing Medication and Testing Consortium (RMTC) and adopted by the Association of Racing Commissioners International (ARCI).
Under 58 Pa. Code § 163.304, the Commission may approve and adopt by reference the RMTC/ARCI schedule of therapeutic medications and their respective threshold levels for use in the thoroughbred horse racing sector of the racing industry. On July 27, 2016, the Commission formally approved the amended Schedule as follows. On December 15, 2013, the Commission previously approved and published at 43 Pa.B. 7612 (December 28, 2013) the original RMTC Schedule. The amended Schedule has been posted and published on the Commission's web site. As the RMTC/ARCI continues to research testing methodologies, therapeutic medications and their various thresholds, the Commission will thereafter publish the amendments or additions, or both.
The Commission did not adopt any withdrawal times related to the enumerated therapeutic medications and the threshold levels. The information on the Schedule does not constitute a guarantee, warranty or assurance that the use of any therapeutic medications at the dosages listed will not result in a positive-race test. Owners, trainers or any other persons responsible for the care, custody and control of a racehorse are strongly encouraged to seek the advice of their respective Veterinarians regarding the use of therapeutic medications.
RMTC
Controlled Therapeutic Medications
Substance Threshold Route of Administration Experimental
Administration DosageAcepromazine HEPS—10 ng/mL of urine Intravenous 0.05 mg/kg Albuterol 1 ng/mL of urine Intra-nasal1 720 mcg total dose Betamethasone 10 pg/mL in plasma or
serumlntra-articular as
betamethasone acetate and betamethasone sodium
phosphate9 mg total in one articular space Butorphanol Free butorphanol—2 ng/mL of plasma, or Total butorphanol—
300 ng/mL of urineIntravenous 0.1 mg/kg Cetirizine 6 ng/mL of plasma/serum Orally 0.4 mg/kg twice daily for five doses Cimetidine 400 ng/mL of plasma or serum Orally 20 mg/kg twice daily for seven doses Clenbuterol 140 pg/mL of urine or LOD in plasma Orally 0.8 mcg/kg Dantrolene 5-OH dantrolene—0.1 ng/mL
of plasma or serumOrally 500 mg total dose Detomidine 1 ng/mL in plasma or serum,
2 ng/mL of carboxydetomidine
in urineIntravenous 5 mg/kg Dexamethasone 5 pg/mL of plasma or serum Oral, Intravenous,
intramuscular0.05 mg/kg Diclofenac 5 ng/mL of plasma or serum Systemic 5" ribbon of Surpass every 12 hours to one site DMSO 10 mcg/mL of plasma or serum Topical Up to 2 ounces Firocoxib 20 ng/mL of plasma or serum Orally 0.1 mg/kg for 4 days Flunixin 20 ng/mL of plasma or serum Intravenous 1.1 mg/kg Furosemide 100 ng/mL in blood and urine specific gravity < 1.010 Intravenous 500 mg total dose Glycopyrrolate 3 pg/mL of plasma or serum Intravenous 1 mg total dose Guaifenesin 12 ng/mL of plasma or serum Orally 2 g twice daily for five doses Isoflupredone 100 pg/mL of serum or plasma Subcutaneous or Intra-articular administration of isoflupredone acetate 10 mg total dose subcutaneous or 20 mg total dose in one articular space Ketoprofen 10 ng/mL of plasma or serum Intravenous 2.2 mg/kg Lidocaine 20 pg/mL of total 30H-lidocaine in plasma Subcutaneous 200 mg of total dose Mepivacaine 3-OH-mepivacaine—10 ng/mL
in urine or mepivacaine at
LOD in plasma or serumSubcutaneous—distal limb 0.07 mg/kg Methocarbamol 1 ng/mL of plasma or serum Intravenous2 15 mg/kg IV, 5 g oral Methylprednisolone 100 pg/mL in plasma or serum Intra-articular as methylprednisolone acetate 100 mg total in one articular space3 Omeprazole Omeprazole sulfide—10 ng/mL
in serum/plasmaOrally 2.2 grams once daily for 4 days Phenylbutazone 2 mcg/mL of plasma or serum Intravenous 4.0 mg/kg Prednisolone 1 ng/mL of plasma or serum Orally 1 mg/kg Procaine penicillin4 25 ng/mL of plasma Intra-muscular 17 mg/kg Ranitidine 40 ng/mL of plasma or serum Orally 8 mg/kg twice daily for seven doses Triamcinolone acetonide 100 pg/mL of plasma or serum Intra-muscular 9 mg total in one articular space Xylazine 0.01 ng/mL of plasma Intravenous 200 mg THOMAS F. CHUCKAS, Jr.,
Director
Bureau of Thoroughbred Horse Racing_______
1 Note: Administration of albuterol other than by intra-nasal routes is not recommended.
2 An oral dose may be utilized but longer withdrawal time may be required to fall below the threshold. Trainers using methocarbamol orally for multiple days are encouraged to have the horse tested prior to entry.
3 At the 100 mg experimental dose, the safe time for administration to fall below the 100 pg/mL threshold was 21 days—a smaller dose may be utilized which may allow plasma concentrations to fall below the threshold in fewer than 21 days.
4 Requires: 1) Mandatory notification of procaine penicillin administration; and 2) Mandatory surveillance at the horse owner's expense for 6 hours before racing. Contact your local racing jurisdiction for specific procedures.
No part of the information on this site may be reproduced for profit or sold for profit.This material has been drawn directly from the official Pennsylvania Bulletin full text database. Due to the limitations of HTML or differences in display capabilities of different browsers, this version may differ slightly from the official printed version.
